SCHEMBL23536292

SCHEMBL23536292

CN(C)S(=O)(=O)c1ccc(C(C)(C)Nc2ccccc2N)cc1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.45
CA1 P00915 2/20 0.43
CA12 O43570 1/20 0.43
CA9 Q16790 1/20 0.43
ALDH1A1 P00352 5/20 0.42
TSHR P16473 1/20 0.42
MAPK1 P28482 1/20 0.42
LMNA P02545 3/20 0.41
CA2 P00918 1/20 0.41
GAA P10253 2/20 0.40
HDAC1 Q13547 1/20 0.39
HSD17B2 P37059 2/20 0.39
UQCRB P14927 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
TRPV4 Q9HBA0 1/20 0.39
CCR6 P51684 1/20 0.38
HTT P42858 1/20 0.38
IMPDH2 P12268 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23536025 0.81 ALDH1A1 (0.62) L3MBTL1CA1CA12CA9ALDH1A1
SCHEMBL29931868 0.81 ALDH1A1 (0.62) L3MBTL1CA1CA12CA9ALDH1A1
SCHEMBL23043640 0.80 MCOLN2 (0.50) L3MBTL1CA1CA9ALDH1A1TSHR
SCHEMBL29979016 0.80 MCOLN2 (0.50) L3MBTL1CA1CA9ALDH1A1TSHR
SCHEMBL29932074 0.79 ALDH1A1 (0.39) CA1CA12CA9ALDH1A1CA2
SCHEMBL94995 0.74 HSD17B2 (0.41) L3MBTL1ALDH1A1MAPK1LMNAGAA
SCHEMBL23536128 0.70 LMNA (0.52) L3MBTL1CA1CA12CA9ALDH1A1
SCHEMBL4409342 0.69 ALDH1A1 (0.57) CA1ALDH1A1TSHRMAPK1LMNA
SCHEMBL23057078 0.69 KMT2A (0.50) L3MBTL1CA1ALDH1A1TSHRMAPK1
SCHEMBL29978300 0.69 KMT2A (0.50) L3MBTL1CA1ALDH1A1TSHRMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230104936-A1 TRPML MODULATORS CASMA THERAPEUTICS, INC. 2023-04-06 US disclosed
EP-4076423-A1 TRPML MODULATORS Casma Therapeutics, Inc. (US) 2022-10-26 EP disclosed
CN-115087440-A TRPML modulators 卡斯玛治疗公司 2022-09-20 CN disclosed
WO-2021127337-A1 TRPML MODULATORS CASMA THERAPEUTICS, INC. (US) 2021-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230104936-A1 TRPML MODULATORS TRPM2, TRPM4, TRPM5 L3MBTL1 3922/4885CA1 1974/4885CA12 3100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.